CTMX

Conviction 4HealthcareScan · Thu, Sep 24, 2026

CytomX Therapeutics, Inc. (CTMX) closed at $2.75 (-1.26%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 36, RS Rating 84, -59.3% from its 52-week high, -35.4% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.

CTMX$2.75-1.26%

ResistanceSupportVol 14

Vol MA14 4.67M

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

CytomX Therapeutics, Inc.PHARMACEUTICAL PREPARATIONSwww.cytomx.com ↗

Price2.75

Change-1.26%

Gap-1.80%

Rel volume1.20×

Avg volume4.52M

Avg $ vol14.11M

SMA 203.20

SMA 503.30

SMA 2004.09

Price vs 50-16.78%

Price vs 200-32.96%

MA stackbearish

50/200 cross—

Supertrenddown · 3.32

RSI (14)36

MACD hist-0.05

MACD crossbear · 9d

Stoch %K / %D8 / 13

ADX (14)22

+DI / −DI17 / 30

RSI divergence—

MACD divergence—

ATR %7.17%

ADR %6.59%

52w high6.75

52w low2.41

From 52w high-59.33%

Above 52w low+13.90%

New 52w highNo

SqueezeOff

Bollinger width47.03%

%B0.20

Donchian pos6.56%

Donchian high3.89

Donchian low2.67

AVWAP (52w high)4.36

vs AVWAP high-36.99%

AVWAP (52w low)4.31

vs AVWAP low-36.37%

OBV trendFlat

Chaikin MF (20)-0.12

Today vs 20d1.20×

Avg vol (14d)4.67M

Avg vol (20d)4.52M

Avg $ vol (20d)14.11M

Market cap598.13M

RS Rating84 / 99

RS 3m (vs SPY)-20.55%

RS 6m (vs SPY)-51.77%

RS line new highNo

Trend template0/8

Technical rank12.8

1 week-2.66%

1 month-18.55%

3 months-16.06%

6 months-34.95%

1 year+30.09%

YTD-35.41%

P/E-34.44

P/B1.98

P/S7.85

P/FCF-7.89

EPS-1.16

Div yield—

ROE-5.75%

ROA-4.56%

Debt/Eq0.01

Current9.36

EV/EBITDA-28.51

Gross margin—

Net margin-22.79%

Rev growth-44.82%

EPS growth-154.50%

Price target13.25

Target upside382.70%

Analyst ratingBuy

Institutional101.81%

Ent. value583.9M

Revenue1.42M

Net income-20.67M

Gross profit—

Free cash flow-75.81M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out217.7M

Employees69

ListedThu, Oct 8, 2015

Free float199.76M

Float %91.8%

Short interest33.51M

Days to cover11.8d

Short volume59.7%

Squeeze score75 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.09 vs −$0.11

Last surprise+18.2% beat

Setup gradeD

Conviction4 / 100

Pattern quality—

Tech rank12.8 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance3.74

Support2.84

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in CTMX

All disclosures →

No recent disclosed trades by Congress in CTMX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in CTMX

Insider	Side	Shares	Value	Traded	Filed
Carvajal Alejandra Chief Legal Officer · Common Stock · 2026-08-03	Grant	100K	—	2026-08-03	2026-08-05
Carvajal Alejandra Chief Legal Officer · Stock Option (Right to Buy) · 2026-08-03	Grant	450K	—	2026-08-03	2026-08-05
Su Zhen Director · Stock Option (Right to Buy) · 2026-06-17	Grant	59K	—	2026-06-17	2026-06-22
Jones Elaine V Director · Stock Option (Right to Buy) · 2026-06-17	Grant	59K	—	2026-06-17	2026-06-22
Gilbert Halley E Director · Stock Option (Right to Buy) · 2026-06-17	Grant	59K	—	2026-06-17	2026-06-22
Ashworth Alan Director · Stock Option (Right to Buy) · 2026-06-17	Grant	59K	—	2026-06-17	2026-06-22
Meyers James R Director · Stock Option (Right to Buy) · 2026-06-17	Grant	59K	—	2026-06-17	2026-06-22
Mohindru Mani Director · Stock Option (Right to Buy) · 2026-06-17	Grant	59K	—	2026-06-17	2026-06-22
Young Matthew P. Director · Stock Option (Right to Buy) · 2026-06-17	Grant	59K	—	2026-06-17	2026-06-22

SEC filings

EDGAR filings in CTMX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.